SMSPHARMA2024-10-012024-12-31 SMSPHARMA2024-10-012024-12-31 SMSPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SMSPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SMSPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SMSPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SMSPHARMA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532815 SMSPHARMA NOTLISTED SMS Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2025-02-12 2025-02-05 INR Lakhs Third quarter 11:30:00 13:55:00 2025-02-12 2025-02-12 Not applicable Single segment Bulk Drugs 2024-10-01 2024-12-31 Unaudited Standalone 1733533000.00 21281000.00 1754814000.00 1182232000.00 0.00 -328306000.00 186449000.00 42030000.00 86956000.00 360133000.00 1529494000.00 225320000.00 0.00 225320000.00 49906000.00 3691000.00 53597000.00 0.00 171723000.00 0.00 0.00 0.00 0.00 171723000.00 151000.00 171874000.00 171874000.00 0.00 84652000.00 1 2.03 2.03 0.00 0.00 2.03 2.03 1 The above standalone un-audited financial results for the quarter ended December 31, 2024 have been reviewed by the Audit Committee on February 11, 2025 and approved by the Board of Directors at their meeting held on February 12, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results for the quarter ended December 31, 2024 and expressed an unmodified conclusion thereon. 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ( SEBI ). (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. 4 During the Quarter,the company has incorporated a subsidiary company namely SMS Peptides Private Limited on November 1, 2024 and there were no operations during the reporting period.Hence ,it is not considered for consolidation. 5 Figures for the previous period have been reclassified/ regrouped wherever necessary to confirm to current period's classification. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 5345526000.00 48003000.00 5393529000.00 3838877000.00 0.00 -951851000.00 534543000.00 134759000.00 256974000.00 937666000.00 4750968000.00 642561000.00 0.00 642561000.00 149906000.00 15067000.00 164973000.00 0.00 477588000.00 0.00 0.00 0.00 0.00 477588000.00 455000.00 478043000.00 478043000.00 0.00 84652000.00 1 5.64 5.64 0.00 0.00 5.64 5.64 Manufacturing Expenses 207568000.00 Other Expenses 152565000.00 Manufacturing Expenses 609424000.00 Other Expenses 328242000.00 -151000.00 -455000.00 0.00 0.00